Focal Intraoperative Radiotherapy of Brain Metastases

Sponsor
AC Camargo Cancer Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03789149
Collaborator
Carl Zeiss Meditec AG (Industry)
33
1
1
31
1.1

Study Details

Study Description

Brief Summary

Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM. In this context, intraoperative radiotherapy (IORT) in the cavity after resection of BM may be an appealing option.

The primary objectives of this study are to evaluate local control (LC) and the control of brain disease (LC associated with the absence of new distant BM) after IORT for one completely resected supratentorial BM in the presence of up to 10 lesions suggestive of BM.

Condition or Disease Intervention/Treatment Phase
  • Radiation: Intraoperative Radiotherapy
Phase 2

Detailed Description

Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors. This type of metastasis occurs in 20-40% of cancer patients and are related to significant morbidity and mortality.

In prospective studies, whole-brain radiotherapy (WBRT) reduced the risk of local recurrence after resection of brain metastases from 46-59% to 10-28%. Furthermore, WBRT reduces the incidence of new metastases and death from disease, but no apparent improvement in overall survival (OS). Due to the potential neurocognitive effects associated with WBRT compared to isolated focal approach, several authors have suggested delaying WBRT and perform focal adjuvant RT after resection of isolated BM.

The utilization of intraoperative radiotherapy (IORT) in the cavity after resection of primary or BM has been described in the literature, the majority of reports describes performing brachytherapy with iodine seeds or interstitial radiosurgery. However, there is a paucity of information regarding the use of IORT with low energy X-ray for focal treatment after resection of brain BM.

The objectives of this study are evaluate local control (LC), the control of brain disease in patients with metastatic brain disease (up to 10 lesions) submitted to focal IORT to an isolated surgical cavity, evaluate overall survival (OS), evaluate the frequency of radiation necrosis and correlate the prognostic factors related to the patient with OS and the parameters of the treatment (dose, volume, lesion location) with the LC and radiation necrosis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
33 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single group assignmentSingle group assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Focal Intraoperative Radiotherapy After Resection of Brain Metastases
Actual Study Start Date :
May 2, 2019
Actual Primary Completion Date :
Jun 15, 2021
Anticipated Study Completion Date :
Nov 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intraoperative Radiotherapy

Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)

Radiation: Intraoperative Radiotherapy
Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
Other Names:
  • Intrabeam
  • Outcome Measures

    Primary Outcome Measures

    1. Local control (LC) [1 year]

      Rate of local failure in the surgical cavity

    2. Control of Brain Disease (CBD) [1 year]

      Rate of control in the brain outside

    Secondary Outcome Measures

    1. Overall Survival (OS) [1 year]

      Rate of death related to any cause

    2. Frequency of radiation necrosis [1 year]

      Imaging evaluation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age >18 years

    • Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM

    • Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection

    • Patient consent to participate in the study

    Exclusion Criteria:
    • Previous cranial radiotherapy

    • Any kind of antineoplasic systemic treatment for less than 7 days of the procedure

    • Cavities with proximity < 10 mm from the brainstem or optical pathway.

    • Pregnant patients

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AC Camargo Cancer Center São Paulo SP Brazil 01509-900

    Sponsors and Collaborators

    • AC Camargo Cancer Center
    • Carl Zeiss Meditec AG

    Investigators

    • Principal Investigator: Douglas G Castro, MD, AC Camargo Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AC Camargo Cancer Center
    ClinicalTrials.gov Identifier:
    NCT03789149
    Other Study ID Numbers:
    • 2315/17
    First Posted:
    Dec 28, 2018
    Last Update Posted:
    Aug 17, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by AC Camargo Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 17, 2021